{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wang LJ"],"funding":["Kaohsiung Chang Gung Memorial Hospital"],"pagination":["227"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8877879"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(2)"],"pubmed_abstract":["This study aimed to examine whether probiotics supplements using <i>Bifidobacterium bifidum</i> (Bf-688) can improve clinical characteristics and gut microbiomes among patients with attention-deficit/hyperactivity disorder (ADHD). This open-label, single-arm trial consisted of 30 children aged 4-16 years who met the criteria for ADHD diagnosis. Each subject took Bf-688, with one sachet in the morning and one in the evening (daily bacteria count 5 × 10<sup>9</sup> CFUs), for 8 weeks. Patients' clinical symptoms were assessed using the Swanson, Nolan, and Pelham Rating Scale (SNAP-IV). We collected stool samples at the baseline, the 8th week, and the 12th week for gut microbiota examination. During the 8-week Bf-688 supplement period, patients' inattention symptoms and hyperactivity/impulsiv"],"journal":["Journal of personalized medicine"],"pubmed_title":["Effect of <i>Bifidobacterium bifidum</i> on Clinical Characteristics and Gut Microbiota in Attention-Deficit/Hyperactivity Disorder."],"pmcid":["PMC8877879"],"funding_grant_id":["CMRPG8K0761 & CMRPG8M0031","CMRPG8K0761 &amp; CMRPG8M0031"],"pubmed_authors":["Chou WJ","Lee SY","Tsai CS","Kuo HC","Wang LJ","Yang CY"],"additional_accession":[]},"is_claimable":false,"name":"Effect of <i>Bifidobacterium bifidum</i> on Clinical Characteristics and Gut Microbiota in Attention-Deficit/Hyperactivity Disorder.","description":"This study aimed to examine whether probiotics supplements using <i>Bifidobacterium bifidum</i> (Bf-688) can improve clinical characteristics and gut microbiomes among patients with attention-deficit/hyperactivity disorder (ADHD). This open-label, single-arm trial consisted of 30 children aged 4-16 years who met the criteria for ADHD diagnosis. Each subject took Bf-688, with one sachet in the morning and one in the evening (daily bacteria count 5 × 10<sup>9</sup> CFUs), for 8 weeks. Patients' clinical symptoms were assessed using the Swanson, Nolan, and Pelham Rating Scale (SNAP-IV). We collected stool samples at the baseline, the 8th week, and the 12th week for gut microbiota examination. During the 8-week Bf-688 supplement period, patients' inattention symptoms and hyperactivity/impulsiv","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Feb","modification":"2025-08-31T03:06:17.252Z","creation":"2025-04-04T13:20:51.191Z"},"accession":"S-EPMC8877879","cross_references":{"pubmed":["35207715"],"doi":["10.3390/jpm12020227"]}}